Is it time to reduce toxicity by non-myeloablative conditioning for allogeneic stem cell transplantation in children?: Editorial

Pediatric Transplantation

Volumn 4, Issue 4, 2000, Pages 247-251

  Svennilson, Johan ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; MELPHALAN; MYELOABLATIVE AGENT;

CHIMERA; CHROMOSOME ABERRATION; EDITORIAL; GRAFT SURVIVAL; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MINIMAL RESIDUAL DISEASE; PROGNOSIS; RADIATION DOSE; RELAPSE; RISK BENEFIT ANALYSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0033787912     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2000.00029.x     Document Type: Editorial

References (45)

1. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival
2. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy
3. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma
4. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas
5. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
6. Late effects of childhood cancer and its treatment
7. Preparative regimens
8. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
9. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
10. The impact of marrow transplant preparative regimens on subsequent growth and development
11. Craniofacial growth in bone marrow transplant recipients with growth hormone after total body irradiation
12. Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation
13. Solid cancers after bone marrow transplantation
14. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis and alopecia using busulfan compared to total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
15. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: A Southwest Oncology Group study
16. A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia
17. Anti-leukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
18. Graft-versus-leukemia reactions after bone marrow transplantation
19. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis
20. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease
21. T-cell depletion of HLA-identical transplants in leukemia
22. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
23. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia
24. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
25. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
26. Molecular evidence of minimal residual disease after treatment for leukemia and lymphoma: An updated meeting report and review
27. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
28. Mixed chimerism in the B-cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B-cell acute lymphoblastic leukemia
29. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction
30. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia
31. Detection of residual bcr/abl translocation by polymerase chain reaction in chronic myeloid leukaemia patients after bone marrow transplantation
32. Non-myelo-ablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
33. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
34. Mixed chimerism: Preclinical studies and clinical applications
35. Evidence of graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
36. Successful treatment of metastatic renal-cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus-tumor effect
37. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission
38. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
39. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
40. Faster neutrophil and platelet engraftment, but no difference in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow
41. Peripheral blood stem cell (PBSC) transplantation from unrelated donors: A comparison with marrow transplantation
42. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
43. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings
44. Workshop Summary: Preparative regimens for allogeneic bone marrow transplantation in leukemia